Scintimammography

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Scintimammography
Diagnostics
Tc99m-sestamibi.jpg
ICD-10-PCS CH1
ICD-9-CM 92.19
HCPCS-L2 S8080

Scintimammography, also known as nuclear medicine breast imaging, breast specific gamma imaging or molecular breast imaging,[1] is a type of breast imaging test that is used to detect cancer cells in the breasts of some women who have had abnormal mammograms, or for those who have dense breast tissue, post-operative scar tissue or breast implants, but is not used for screening or in place of a mammogram. Rather, it is used when the detection of breast abnormalities is not possible or not reliable on the basis of mammography and ultrasound. In the scintimammography procedure, a woman receives an injection of a small amount of a radioactive substance called technetium 99 sestamibi,[2] which is taken up by cancer cells, and a gamma camera is used to take pictures of the breasts.

Also called a Miraluma test (when with sestamibi)[3] and sestamibi breast imaging.

See also[edit]

References[edit]

  1. ^ "Scintimammography". RadiologyInfo.org. Retrieved 4 November 2014. 
  2. ^ Nass, Sharyl J.; Henderson, I. Craig; Cancer, Institute of Medicine (U.S.). Committee on Technologies for the Early Detection of Breast (2001). Mammography and beyond: developing technologies for the early detection of breast cancer. National Academies Press. pp. 106–. ISBN 978-0-309-07283-0. Retrieved 17 July 2011. 
  3. ^ Tartar, Marie; Comstock, Christopher E.; Kipper, Michael S. (2008). Breast cancer imaging: a multidisciplinary, multimodality approach. Elsevier Health Sciences. pp. 88–. ISBN 978-0-323-04677-0. Retrieved 18 July 2011. 

External links[edit]

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".